Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States
- 28 February 2009
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 63 (2) , 264-270
- https://doi.org/10.1016/j.lungcan.2008.05.003
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignanciesClinical Therapeutics, 2006
- A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): Update of the Alpha Oncology trial (A1–99002L)Journal of Clinical Oncology, 2005
- Chemotherapy Use, Outcomes, and Costs for Older Persons With Advanced Non–Small-Cell Lung Cancer: Evidence From Surveillance, Epidemiology and End Results–MedicareJournal of Clinical Oncology, 2004
- Population Variations in the Initial Treatment of Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Who Gets Chemotherapy for Metastatic Lung Cancer?Chest, 2000
- A comparison of patterns of care of nonsmall cell lung carcinoma patients in a younger and Medigap commercially insured cohortCancer, 1998
- New aspects in the staging of lung cancer. Prospective validation of the international union against cancer TNM classificationCancer, 1992
- A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study.Journal of Clinical Oncology, 1991
- Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.Journal of Clinical Oncology, 1988